Optimization of a Low Cost and Broadly Sensitive Genotyping Assay for HIV-1 Drug Resistance Surveillance and Monitoring in Resource-Limited Settings

被引:86
作者
Zhou, Zhiyong [1 ]
Wagar, Nick [1 ]
Devos, Joshua R. [1 ]
Rottinghaus, Erin [1 ]
Diallo, Karidia [1 ]
Nguyen, Duc B. [2 ]
Bassey, Orji [3 ]
Ugbena, Richard [3 ]
Wadonda-Kabondo, Nellie [4 ]
McConnell, Michelle S. [1 ,5 ]
Zulu, Isaac [6 ]
Chilima, Benson [4 ]
Nkengasong, John [1 ]
Yang, Chunfu [1 ]
机构
[1] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA
[2] Dept Hlth & Human Serv US CDC, Hanoi, Vietnam
[3] CDC GAP, Abuja, Nigeria
[4] Malawi Minist Hlth, Community Hlth Sci Unit, Lilongwe, Malawi
[5] Thailand Minist Publ Hlth US CDC Collaborat, Nonthaburi, Thailand
[6] Global AIDS Program CDC Zambia, Lusaka, Zambia
来源
PLOS ONE | 2011年 / 6卷 / 11期
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; DRIED BLOOD SPOTS; WORLD-HEALTH-ORGANIZATION; SEQUENCE-BASED ANALYSIS; ANTIRETROVIRAL TREATMENT; SUBTYPE-A; MUTATIONS; PERFORMANCE; SYSTEM; PLASMA;
D O I
10.1371/journal.pone.0028184
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Commercially available HIV-1 drug resistance (HIVDR) genotyping assays are expensive and have limitations in detecting non-B subtypes and circulating recombinant forms that are co-circulating in resource-limited settings (RLS). This study aimed to optimize a low cost and broadly sensitive in-house assay in detecting HIVDR mutations in the protease (PR) and reverse transcriptase (RT) regions of pol gene. The overall plasma genotyping sensitivity was 95.8% (N = 96). Compared to the original in-house assay and two commercially available genotyping systems, TRUGENE (R) and ViroSeq (R), the optimized in-house assay showed a nucleotide sequence concordance of 99.3%, 99.6% and 99.1%, respectively. The optimized in-house assay was more sensitive in detecting mixture bases than the original in-house (N=87, P<0.001) and TRUGENE (R) and ViroSeq (R) assays. When the optimized in-house assay was applied to genotype samples collected for HIVDR surveys (N = 230), all 72 (100%) plasma and 69 (95.8%) of the matched dried blood spots (DBS) in the Vietnam transmitted HIVDR survey were genotyped and nucleotide sequence concordance was 98.8%; Testing of treatment-experienced patient plasmas with viral load (VL) >= and < 3 log10 copies/ml from the Nigeria and Malawi surveys yielded 100% (N=46) and 78.6% (N = 14) genotyping rates, respectively. Furthermore, all 18 matched DBS stored at room temperature from the Nigeria survey were genotyped. Phylogenetic analysis of the 236 sequences revealed that 43.6% were CRF01_AE, 25.9% subtype C, 13.1% CRF02_AG, 5.1% subtype G, 4.2% subtype B, 2.5% subtype A, 2.1% each subtype F and unclassifiable, 0.4% each CRF06_CPX, CRF07_BC and CRF09_CPX. Conclusions: The optimized in-house assay is broadly sensitive in genotyping HIV-1 group M viral strains and more sensitive than the original in-house, TRUGENE (R) and ViroSeq (R) in detecting mixed viral populations. The broad sensitivity and substantial reagent cost saving make this assay more accessible for RLS where HIVDR surveillance is recommended to minimize the development and transmission of HIVDR.
引用
收藏
页数:10
相关论文
共 52 条
  • [1] Abegaz WE, 2008, ANTIVIR THER, V13, P89
  • [2] High Failure Rate of the ViroSeq HIV-1 Genotyping System for Drug Resistance Testing in Cameroon, a Country with Broad HIV-1 Genetic Diversity
    Aghokeng, Avelin F.
    Mpoudi-Ngole, Eitel
    Chia, Julius E.
    Edoul, Elvine M.
    Delaporte, Eric
    Peeters, Martine
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (04) : 1635 - 1641
  • [3] Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes
    Beddows, S
    Galpin, S
    Kazmi, SH
    Ashraf, A
    Johargy, A
    Frater, AJ
    White, N
    Braganza, R
    Clarke, J
    McClure, M
    Weber, JN
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2003, 70 (03) : 337 - 342
  • [4] BENNETT DE, 2008, PLOS ONE S2, V13, pE4724
  • [5] Bennett DE, 2008, ANTIVIR THER, V13, P1
  • [6] The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world
    Bennett, Diane E.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (06) : 607 - 614
  • [7] Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
    Bennett, Diane E.
    Camacho, Ricardo J.
    Otelea, Dan
    Kuritzkes, Daniel R.
    Fleury, Herve
    Kiuchi, Mark
    Heneine, Walid
    Kantor, Rami
    Jordan, Michael R.
    Schapiro, Jonathan M.
    Vandamme, Anne-Mieke
    Sandstrom, Paul
    Boucher, Charles A. B.
    van de Vijver, David
    Rhee, Soo-Yon
    Liu, Tommy F.
    Pillay, Deenan
    Shafer, Robert W.
    [J]. PLOS ONE, 2009, 4 (03):
  • [8] Bertagnolio S, 2010, AIDS REV, V12, P195
  • [9] Bertognolio S, 2008, ANTIVIR THER, V13, P49
  • [10] New methods for the surveillance of HIV drug resistance in the resource poor world
    Buckton, Andrew J.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2008, 21 (06) : 653 - 658